Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMELINA: Linagliptin CV and Renal Outcomes in T2DM
NCT01897532Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin with Placebo (2 arms). Primary endpoint: Time to First Occurrence of 3-point Major Adverse Cardiovascular Events up to 4.3 years. Started Jul 2013; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01897532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897532.